Enanta Pharmaceuticals | ENTA - Ebitda


Enanta Pharmaceuticals reported $-36.06M in EBITDA for its fiscal quarter ending in June of 2023.





Ebitda Change Date
AbbVie USD 3.69B 1.68B Mar/2026
Amgen USD 3.86B 1.28B Mar/2026
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD -147.68M 40.33M Jun/2026
AstraZeneca USD 5.16B 510M Jun/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Biogen USD 649.7M 76.5M Mar/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Gilead Sciences USD 3.51B 489M Mar/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Halozyme Therapeutics USD 328.81M 109.24M Jun/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Immunic USD -22.78M 753K Jun/2024
Incyte USD 778.57M 410.6M Jun/2026
Insmed USD -148.3M 165.88M Mar/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
J&J USD 8.27B 1.08B Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD -14.3M 81.08M Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 6.01B 18M Jun/2026
PTC Therapeutics USD 61.98M 132.97M Mar/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026